Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

NCT ID: NCT05337332

Last Updated: 2022-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-14

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Serous Chorioretinopathy Irvine-Gass Syndrome Pars Planitis Cystoid Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Central serous chorioretinopathy group

Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.

Group Type EXPERIMENTAL

Triamcinolone Acetonide

Intervention Type DRUG

Suprachoroidal injection of triamcinolone acetonide

Irvine-Gass Syndrome group

Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide

Group Type EXPERIMENTAL

Triamcinolone Acetonide

Intervention Type DRUG

Suprachoroidal injection of triamcinolone acetonide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone Acetonide

Suprachoroidal injection of triamcinolone acetonide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Suprachoroidal triamcinolone acetonide injection (SCTA)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery.

Exclusion Criteria

* other retinal diseases that may affect CMT and final visual outcome.
* Patients with dense corneal opacity.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Abdelshafy

Assistant professor of Ophthalmology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed A Abdelshafy, MD

Role: PRINCIPAL_INVESTIGATOR

Benha University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ahmed Abdelshafy

Banhā, QA, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed Abdelshafy, MD

Role: CONTACT

01222328766

Marwa Abdelshafy, MD

Role: CONTACT

01222328766

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed Abdelshafy

Role: primary

01222328766

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC 7-7-22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical Cyclosporine-A for Management of Epiphora
NCT04637633 COMPLETED PHASE2/PHASE3
Herpetic Eye Disease Study (HEDS) I
NCT00000138 UNKNOWN PHASE3